Whether you perform integrated drug discovery project, product development process or aim for characterization of protein-ligand binding, Selvita provides services with the range of biophysical methods that allow to carry screening of low-to-medium size libraries or determine binding affinities and kinetics of ligand interaction with target.
In a screening campaign for hit identification Selvita utilizes combination of simple Fluorescence Thermal Shift Assay (FTSA) using Real-Time PCR System QuantStudio TM 6 Flex and more advanced Surface Plasmon Resonance (SPR) technology with the help of BiacoreT200TM instrumentation in up to 384-well format. The candidates selected from the screening further studied in dose response kinetic analysis by SPR that provides valuable information about “on” and “off” kinetics as well as binding affinity at equilibrium. Our BiacoreT200 allows to perform real-time label-free measurements of wide range of molecular interactions including challenging targets such as membrane proteins. Biacore instrument also is great tool in antibodies and other protein-based biotherapeutics development suitable for analysis of kinetics with the fastest “on”-rates to the slowest “off”-rates.
To confirm binding of selected lead molecules to their target, we apply another orthogonal method such as Isothermal Titration Calorimetry (ITC), using the MicroCal PEAQ-ITC instrument, which provides essential thermodynamic information on ligand binding to its target. Known as a gold standard in binding studies this method delivers all binding parameters (affinity, stoichiometry, enthalpy and entropy) in a single measurement allowing to measure almost any type of interactions in solution with millimolar to picomolar affinities. As a very sensitive and reproducible method with little assay development effort ITC serves well in SAR studies, and also can facilitate support of the SBDD and FBDD together with X-ray crystallography.
Our experienced biophysical team supports development of the assays for customer needs as well as carry out adaptation of existing protocols and their validation. The platform allows to run projects in biotherapeutics and small molecules discovery, hit-to-lead development, comparative studies of biosimilars as standalone platform or by validation of results obtained in biochemical or cell-based assays.